Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + levofolinate calcium + 5-fluorouracil + bevacizumab
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Oxaliplatin + levofolinate calcium + 5-fluorouracil + bevacizumab is a multi-drug combination chemotherapy regimen, commonly referred to as mFOLFOX6 plus bevacizumab, used primarily for the treatment of unresectable, advanced, or recurrent colorectal cancer (mCRC). The regimen consists of the mFOLFOX6 backbone—comprising oxaliplatin (a platinum-based alkylating agent that induces DNA crosslinking), 5-fluorouracil (an antimetabolite that inhibits thymidylate synthase), and levofolinate calcium (a folate derivative that potentiates the activity of 5-fluorouracil)—combined with bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis. This combination therapy is designed to simultaneously disrupt DNA synthesis and the tumor's blood supply. Takeda has been a significant sponsor in clinical trials, such as the Phase III PARADIGM study, which evaluated this regimen as a first-line treatment in patients with RAS wild-type metastatic colorectal cancer.
- Other names
- mFOLFOX6-bevacizumabmFOLFOX-6-bevacizumabmFOLFOX 6-bevacizumabFOLFOX-bevacizumab
02
Targets
Beyond the preview
Go deeper on oxaliplatin + levofolinate calcium + 5-fluorouracil + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + levofolinate calcium + 5-fluorouracil + bevacizumab.